Monaghan Medical Introduces Manometer Adapter to Measure Treatment with Aerobika® OPEP Device

New Adapter Tracks Airway Pressure Visually, Ensuring Therapeutic Effectiveness of Respiratory Treatment.

Plattsburgh, NY, USA (January 21, 2016) -- Monaghan Medical Corporation (MMC) (, a leader in the development, manufacture, and marketing of respiratory devices, today announced the release of a new Manometer Adapter for its Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device-a drug-free, clinically supported device that reduces coughing and breathlessness, increases lung hygiene, and improves gas transfer. The Manometer Adapter serves as a visual compliance tool for the Aerobika® OPEP to assist respiratory therapists and patients in assessing respiratory therapy that calls for active exhalation.

The MMC Aerobika® OPEP device improves respiration by clearing mucus from the lungs through exhalation. OPEP therapy is highly effective in postoperative patients for airway clearance and lung hygiene, and for patients with chronic respiratory conditions such as cystic fibrosis. With the addition of a Manometer Adapter, respiratory therapists, clinicians, and patients can literally see with their own eyes how well the patient is using the device.

The Aerobika® OPEP device works by using active exhalation: The patient wraps his or her mouth around the OPEP mouthpiece and exhales, while the device uses pulses of air resistance to release mucus trapped in smaller air pathways. The Manometer Adapter allows clinicians to measure the pressure exerted by active exhalation to determine therapeutic effectiveness. It is ideal for clinical training, ensuring that the OPEP device is used properly.

The Manometer Adapter-which has an easy-to-read scale that shows green when active exhalation is in the target zone of 5 cm to 20 cm H2O-provides immediate patient feedback and confirms that the patient is achieving therapeutic pressure every time the OPEP device is used.

"Postoperative patients and patients with severe respiratory conditions needed a new kind of respiratory treatment," says Dom Coppolo, Vice President of Clinical Strategy and Development at Monaghan Medical Corporation. "That's why we developed the Aerobika® OPEP Therapy System-to help treat ailments with a productive cough seeking a non-therapeutic method of removing mucus from the lungs. With the addition of the Manometer Adapter, we now have an OPEP device that is easy to use and easy to monitor. The Manometer Adapter provides a baseline for active exhalation therapy so practitioners can measure patients' recovery progress.

"We are committed to providing products that ensure patients continue treatment and control their symptoms," Coppolo says. "Providing metrics to measure treatment efficacy only speeds recovery."

The Aerobika® OPEP is suitable for various patient treatments, such as post-operative thoracic recovery, lung volume expansion therapy, and atelectasis treatment, reducing the risk of pulmonary complications. The Aerobika® OPEP is easy to use, has no side effects or interactions since it is drug-free, and, with the new Manometer Adapter, makes it easier than ever to monitor therapeutic pressure levels.

For more information, visit

About Monaghan Medical
Monaghan Medical Corporation (MMC), headquartered in Plattsburgh, New York (USA), is a leader in the development, manufacture, and marketing of respiratory devices, from the flagship AeroChamber® Brand of Valved Holding Chamber (VHC) for asthma patients to the latest state-of-the-art Aerobika® OPEP therapy. MMC's products are developed and validated by its sister company's world-renowned Trudell Medical Aerosol Institute and are supported by more than 500 peer reviewed and published articles.

Dominic P. Coppolo
Vice President of Clinical Strategy and Development
Monaghan Medical Corporation